Tango Therapeutics Announced That The First Patient Has Been Dosed In The Phase 1/2 Trial Of TNG260 In Combination With Pembrolizumab In Patients With STK11-mutant Cancers
Portfolio Pulse from Benzinga Newsdesk
Tango Therapeutics has announced the dosing of the first patient in the Phase 1/2 trial of TNG260 in combination with Pembrolizumab for STK11-mutant cancers. This marks a significant step in the development of the drug.
July 24, 2023 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics' progress in the Phase 1/2 trial of TNG260 could potentially impact the company's stock positively as it marks a significant step in the drug's development.
The announcement of the first patient being dosed in the Phase 1/2 trial of TNG260 is a significant milestone in the drug's development. This could potentially lead to positive investor sentiment and a rise in Tango Therapeutics' stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100